Healthcare Industry News: AngioSculpt
News Release - January 25, 2013
AngioScore Launches New 100 mm Length AngioSculpt(R) Scoring Balloons For Treatment of Peripheral Artery Disease Below The Knee (BTK)FREMONT, Calif.--(Healthcare Sales & Marketing Network)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD) below the knee (BTK).
These new AngioSculpt catheters have received U.S. Food and Drug Administration (FDA) 510(k) clearance to market for the dilatation of lesions in the iliac; femoral; iliofemoral; popliteal; infra-popliteal; and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. They are not labeled for use in the coronary or neuro-vasculature.
The catheters incorporate longer 100 mm Scoring Balloons in diameters of 2.0, 2.5, 3.0 and 3.5 mm. These catheters are expected to be particularly useful in treating complex lesions typically encountered in the treatment of patients with critical limb ischemia (CLI) and infra-popliteal PAD. Thomas P. Davis, M.D., Director of the Cardiac Catheterization Lab and Director of Peripheral Interventions and Disease at St. John Hospital and Medical Center (Detroit, Mich.), commented: “These longer AngioSculpt Scoring Balloon Catheters provide physicians with important new devices for the treatment of challenging lesions below the knee because of their ability to achieve more predictable luminal expansion and a very low rate of dissection, potentially minimizing the need to perform adjunctive stenting.”
Thomas R. Trotter, president and CEO of AngioScore, added: “The peripheral artery disease market is a rapidly growing segment of the interventional cardiovascular market. Over a million percutaneous peripheral procedures are now being performed annually worldwide, and the PAD market continues to demonstrate significant growth due to improved diagnosis and the increasing prevalence of important risk factors such as adult onset diabetes mellitus. We believe that the AngioSculpt line of Scoring Balloon Catheters is particularly useful in treating this very challenging and serious disease.”
About AngioSculpt Scoring Balloon Catheters
The AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty balloon catheters for the treatment of both coronary and peripheral artery disease. Their innovative nitinol scoring elements provide unique circumferential scoring of plaque, leading to precise and predictable luminal enlargement across a wide range of lesion types while avoiding “geographic miss” through their unique anti-slippage properties. The AngioSculpt balloon catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of traditional high-performance balloon catheters.
AngioSculpt devices have now been used in more than 250,000 procedures worldwide and have achieved an outstanding performance record in the treatment of both coronary and peripheral artery disease.
AngioScore, Inc (www.angioscore.com) is a privately funded endovascular company located in Fremont, California. AngioScore can be contacted at (510) 933-7900 or email@example.com.
Note: This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Actual results and timing of events could differ materially from current expectations and forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.